Known to affect the blood-forming stem cells or progenitor cells, acute myeloid leukemia (AML) is a malignant disease characterized by the disrupted differentiation and excessive growth of myeloid lineages. According to reports, although a rare disease accounting for about 1% of all cancers worldwide, AML is the most common form of leukemia in adults.
A fatal disease, AML patients face the lowest survival rates of all leukemias, with only one in four adults surviving longer than five years after the diagnosis.1,2 In 2020, AML accounted for approximately 25% of all leukemia cases worldwide.2 Of those cases, the median age of diagnosis was above 65 years.3
Upon diagnosis, treatment options and recommendations for patients will depend on a variety of factors, such as the type, stage, possible side effects, and overall health. Chemotherapy is typically used in conjunction with targeted drug therapy to treat most AML subtypes followed by stem cell transplant.
Since 2016, biopharma companies have initiated over 1,000 AML clinical trials globally, with the Asia Pacific region involved in about 30% of the trials. Access this report to better understand the incidence, distribution, and possible control of AML in the Asia Pacific region, the standard of care, the trial landscape, and more.